What is CompleWare?
CompleWare operates as a sophisticated global provider of clinical trial endpoint services, maintaining a specialized focus on the complex therapeutic domains of ophthalmology, respiratory, and oncology. By bridging the gap between clinical research organizations, pharmaceutical entities, and biotech innovators, the company facilitates the delivery of high-integrity data through its proprietary, cloud-based software architecture. This technological infrastructure enables real-time data accessibility and rigorous regulatory compliance, effectively removing the traditional geographic barriers that often impede global clinical research. Through its commitment to precision and reliability, CompleWare serves as a critical partner in the advancement of novel therapeutic options for patients on a global scale.
How much funding has CompleWare raised?
CompleWare has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in CompleWare
PPP
Public-Private Partnership
What's next for CompleWare?
Following this late-stage capital infusion, CompleWare is poised to transition into a phase of aggressive market expansion and technological refinement. The strategic allocation of these funds will likely prioritize the enhancement of its cloud-based software suite to support increasingly complex trial protocols and the integration of advanced analytical capabilities. As the company continues to solidify its position as a leader in endpoint services, the focus will shift toward deepening its penetration within the oncology and respiratory sectors, where the demand for high-fidelity clinical data remains at an all-time high. By leveraging this financial backing, CompleWare is set to strengthen its competitive moat and drive long-term value for its stakeholders in the global life sciences ecosystem.
See full CompleWare company page
